- By insider

President and CEO of Intellia Therapeutics Inc (30-Year Financial, Insider Trades) John M Leonard (insider trades) sold 50,000 shares of NTLA on 11/25/2020 at an average price of $36 a share. The total sale was $1.8 million.

• Warning! GuruFocus has detected 4 Warning Sign with NTLA. Click here to check it out.

• NTLA 15-Year Financial Data

• The intrinsic value of NTLA

• Peter Lynch Chart of NTLA

Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. Intellia Therapeutics Inc has a market cap of $2.12 billion; its shares were traded at around $35.86 with and P/S ratio of 30.89. GuruFocus has detected 1 severe warning sign with Intellia Therapeutics Inc. .

CEO Recent Trades:

• President and CEO John M Leonard sold 50,000 shares of NTLA stock on 11/25/2020 at the average price of $36. The price of the stock has decreased by 0.39% since.

• President and CEO John M Leonard sold 20,000 shares of NTLA stock on 11/16/2020 at the average price of $34. The price of the stock has increased by 5.47% since.

• President and CEO John M Leonard sold 50,000 shares of NTLA stock on 11/04/2020 at the average price of $26. The price of the stock has increased by 37.92% since.

Directors and Officers Recent Trades:

• EVP, General Counsel Jose E Rivera sold 6,653 shares of NTLA stock on 11/18/2020 at the average price of $34.36. The price of the stock has increased by 4.37% since.

• EVP, General Counsel Jose E Rivera sold 3,364 shares of NTLA stock on 11/04/2020 at the average price of $28. The price of the stock has increased by 28.07% since.

For the complete insider trading history of NTLA, click here

.This article first appeared on GuruFocus.